News >

Subcutaneous Daratumumab Succeeds in Phase III Myeloma Trial

OncLive Staff
Published: Monday, Feb 25, 2019

Jan van de Winkel, PhD
Jan van de Winkel, PhD
A subcutaneous (SC) formulation of daratumumab is noninferior in inefficacy and pharmacokinetics compared with standard intravenous (IV) daratumumab (Darzalex) in patients with relapsed/refractory multiple myeloma, according to data from the phase III COLUMBA study.1

Additionally, the safety profiles were similar across both dosing regimens.


  1. Genmab Announces Positive Topline Results in Phase III COLUMBA Study of Subcutaneous Daratumumab. Published February 25, 2019. Accessed February 25, 2019.
  2. Chari AJ, Martinez-Lopez J, Mateos MV, et al. Daratumumab (DARA) in combination with carfilzomib and dexamethasone (D-Kd) in lenalidomide (Len)-refractory patients (Pts) with relapsed multiple myeloma (MM): Subgroup analysis of MMY1001. J Clin Oncol. 2018;36 (suppl; abstr 8002).

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 22nd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and MyelomaMay 30, 20192.0
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Publication Bottom Border
Border Publication